HHS Announces More Than $1.5 Billion State and Tribal Opioid Response Funding Opportunities

The 2024 SOR funding opportunity includes initiatives to:

• Build on opioid overdose reversal medication (naloxone and nalmefene) saturation efforts, ensuring these medications are in the hands of those most likely to witness an overdose.
• Increase the focus on the full continuum of prevention, harm reduction, treatment, and recovery support services for transitional aged youth and young adults (ages 16-25).
• Expand access to MOUD in correctional settings.
• Emphasize the provision of services using a whole-person approach, taking into account an individual’s physical and mental health needs and their social supports.

SOR awards will help states and territories build on successes from previous grants. From 2018 to 2023, SOR recipients have reported:

• Over 550,000 overdose reversals
• About 9.8 million naloxone kits and 7 million fentanyl test strips distributed
• Over 1.2 million people received treatment services and over 600,000 people received MOUD, including buprenorphine, methadone, and injectable extended-release naltrexone.
• At their six month follow up, 78% of people who received treatment through SOR reported they did not use illicit drugs.

TOR awards will also help Tribal communities continue to build on successes since 2018, including:

• Providing treatment and recovery support to over 11,000 people
• Distributing almost 50,000 naloxone kits and 37,000 fentanyl test strips
• Furnishing prevention resources to over 78,000 people.

In order to help recipients better plan and implement overdose response activities, SOR awards will be extended from two to three years, and TOR awards will be extended from two to five years.